Short-Course Therapy with Daily Rifapentine in a Murine Model of Latent Tuberculosis Infection

作者
Tianyu Zhang,Ming Zhang,Ian M. Rosenthal,J Grosset,Eric L. Nuermberger
出处
期刊:American Journal of Respiratory and Critical Care Medicine [American Thoracic Society]
卷期号:180 (11): 1151-1157 被引量:73
标识
DOI:10.1164/rccm.200905-0795oc
摘要

RATIONALE: Regimens recommended to treat latent tuberculosis infection (LTBI) are 3 to 9 months long. A 2-month rifampin+pyrazinamide regimen is no longer recommended. Shorter regimens are highly desirable. Because substituting rifapentine for rifampin in the standard regimen for active tuberculosis halves the treatment duration needed to prevent relapse in mice, we hypothesized daily rifapentine-based regimens could shorten LTBI treatment to 2 months or less. OBJECTIVES: To improve an existing model of LTBI chemotherapy and evaluate the efficacy of daily rifapentine-based regimens. METHODS: Mice were immunized with a more immunogenic recombinant Bacille Calmette-Guérin strain (rBCG30) and received very low-dose aerosol infection with Mycobacterium tuberculosis to establish a stable lung bacterial burden below 10(4) CFU without drug treatment. Mice received a control (isoniazid alone, rifampin alone, rifampin+isoniazid, rifampin+pyrazinamide) or test (rifapentine alone, rifapentine+isoniazid, rifapentine+pyrazinamide, rifapentine+isoniazid+pyrazinamide) regimen for 8 weeks. Rifamycin doses were 10 mg/kg/d, analogous to the same human doses. Outcomes were biweekly lung CFU counts and relapse after 4 to 8 weeks of treatment. MEASUREMENTS AND MAIN RESULTS: M. tuberculosis CFU counts remained stable around 3.65 log(10) in immunized, untreated mice. Isoniazid or rifampin left all or most mice culture-positive at week 8. Rifampin+isoniazid cured 0 and 53% of mice and rifampin+pyrazinamide cured 47 and 100% of mice in 4 and 8 weeks, respectively. Rifapentine-based regimens were more active than rifampin+isoniazid and indistinguishable from rifampin+pyrazinamide. CONCLUSIONS: In this improved murine model of LTBI chemotherapy with very low lung burden, existing regimens were well represented. Daily rifapentine-based regimens were at least as active as rifampin+pyrazinamide, suggesting they could effectively treat LTBI in 6 to 8 weeks.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
v0id应助汪汪采纳,获得10
1秒前
1秒前
小药丸完成签到,获得积分10
1秒前
丘比特应助傅礼貌采纳,获得10
1秒前
科研狗应助Crystal采纳,获得30
2秒前
xuan发布了新的文献求助10
2秒前
宗笑晴完成签到,获得积分10
3秒前
甜甜圈完成签到,获得积分10
3秒前
沉默星星完成签到 ,获得积分10
3秒前
Orange应助xiaolu采纳,获得10
3秒前
123456发布了新的文献求助10
4秒前
4秒前
动听无声完成签到,获得积分10
4秒前
4秒前
鲨鱼辣椒发布了新的文献求助10
4秒前
充电宝应助并不浓妆的狸猫采纳,获得150
4秒前
hellozijia完成签到,获得积分10
5秒前
Lucas应助GLFCX采纳,获得10
5秒前
坦率的鸡翅完成签到 ,获得积分10
5秒前
5秒前
5秒前
郁香薇完成签到,获得积分10
6秒前
6秒前
xhh完成签到,获得积分10
6秒前
锦鲤中的欧皇完成签到 ,获得积分10
7秒前
小怪兽完成签到,获得积分10
7秒前
7秒前
7秒前
8秒前
cz完成签到,获得积分10
8秒前
Zoe完成签到,获得积分10
8秒前
Forever完成签到,获得积分10
8秒前
123456发布了新的文献求助10
8秒前
xuan发布了新的文献求助10
9秒前
9秒前
生动的中心完成签到 ,获得积分10
9秒前
9秒前
wobuxin完成签到,获得积分10
10秒前
滑稽帝完成签到,获得积分10
10秒前
乐乐应助科研通管家采纳,获得10
11秒前
高分求助中
Markov Chain Monte Carlo 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Common Foundations of American and East Asian Modernisation: From Alexander Hamilton to Junichero Koizumi 5000
Matrix Methods in Data Mining and Pattern Recognition Second Edition 610
政治传播过程中的外交与说服——以中苏友好协会为例的历史考察 566
Discerning Saints: Moralization of Intrinsic Motivation and Selective Prosociality at Work 500
Handbuch Trainingswissenschaft – Trainingslehre 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7580420
求助须知:如何正确求助?哪些是违规求助? 9159978
关于积分的说明 19597009
捐赠科研通 7163143
什么是DOI,文献DOI怎么找? 3265875
关于科研通互助平台的介绍 2430782
邀请新用户注册赠送积分活动 2256832